According to the Global HPAPIs and Cytotoxic Drugs Manufacturing Market, by Drug Origin (Chemical-based HPAPIs and Biologic-based HPAPIs), by Manufacturing Location (In-house Manufacturing and Outsourcing), by Drug Type (Novel HPAPIs and Generic HPAPIs), by Type of Pharmacological Molecule (Small Molecules and Biologics), by Application (Oncology, Respiratory, Ophthalmic Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 51.53 Billion in 2022 and is expected to exhibit a CAGR of 8.0% during the forecast period (2022-2030).
Market players are indulged in launching new products in the HPAPIs and cytotoxic drugs, this is expected to increase the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in March 2018, Pfizer CentreOne, contract development and manufacturing organization (CDMO) launched Enviero progesterone in active pharmaceutical ingredients (API) market, which reduces waste and greenhouse gas emissions, and use of harmful solvents. Enviero progesterone from Pfizer CentreOne is available in particle sizes for a broad range of pharmaceutical applications: Enviero Progesterone micronized for soft gel, Enviero Progesterone USP micronized and Enviero Progesterone USP
Market players are indulged in inauguration of the new manufacturing facility for the production of the cytotoxic drugs. This is expected to increase the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in June 2021, Cerbios-Pharma SA, a pharmaceutical company, announced the approval of its HPAPI plant by Swissmedic (national authorization and supervisory authority for drugs and medical products), which features reactors up to 1000 L and pressure-filter-dryer, which will extend the manufacturing capacity and complement the existing HPAPI facilities with a broad range of batch sizes and services.
Global HPAPIs and Cytotoxic Drugs Manufacturing Market- Impact of Coronavirus (COVID – 19) Pandemic
The coronavirus disease (COVID-19) pandemic is expected to restrain growth of the global HPAPIs and cytotoxic drugs manufacturing market over the forecast period. COVID-19 is the recent pandemic outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO) Weekly epidemiological update on COVID-19, the number of new cases are decreasing after the May 1, 2022. Therefore, as of May 1, 2022, around 500 million cases and over 6 million deaths have been reported.
The U.S. FDA continues to take steps to monitor the supply chain. The Center for Drug Evaluation and Research (CDER) Drug Shortage Staff has asked manufacturers to evaluate their entire supply chain, including active pharmaceutical ingredients, finished dose forms, and any components that may be impacted in China or in other areas of the supply chain due to the coronavirus (COVID-19). Furthermore, after the end of the Covid-19 pandemic, some organizations will try to increase their output, in order to meet the increased demand of HPAPIs and cytotoxic drugs. To compensate for the losses incurred during the crisis, key players are expected to hire contract development and manufacturing teams. Furthermore, a number of government agencies are developing novel initiatives to assist the expansion of contract development and manufacturing firms, so that smaller firms may help larger firms increase their efficiency.
Browse 48 Market Data Tables and 35 Figures spread through 309 Pages and in-depth TOC on Global HPAPIs and Cytotoxic Drugs Manufacturing Market, by Drug Origin (Chemical-based HPAPIs and Biologic-based HPAPIs), by Manufacturing Location (In-house Manufacturing and Outsourcing), by Drug Type (Novel HPAPIs and Generic HPAPIs), by Type of Pharmacological Molecule (Small Molecules and Biologics), by Application (Oncology, Respiratory, Ophthalmic Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the HPAPIs and cytotoxic drugs manufacturing market, click the link below:
Market players are indulged in inorganic strategies such as signing agreements for the production of cytotoxic drugs. This is expected to increase the growth of the market, over the forecast period. In July 2021, Novasep, announced signing a manufacturing services agreement with Exelixis, a commercially successful, oncology-focused U.S.-based biotechnology company for the cGMP clinical production of XB002, a next-generation tissue factor-targeting antibody-drug conjugate (ADC) for oncology applications. XB002 is a novel ADC composed of a human monoclonal antibody against tissue factor, which is conjugated to a cytotoxic agent and leverages proprietary linker-payload technology.
Key Takeaways of the HPAPIs and Cytotoxic Drugs Manufacturing Market:
- The global HPAPIs and cytotoxic drugs manufacturing market is expected to exhibit a CAGR of 8.0% over the forecast period (2022-2030), owing to growth in potential markets, especially in Europe. While North America accounted for the major market share.
- Market players are indulged in launching new products and this is expected to increase the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in June 2020, Ajinomoto Bio-Pharma Services announced the launch of AJILITY, a flexible and agile drug product manufacturing platform, designed to manufacture advanced vaccines and therapies.
- Some of the major players operating in the global HPAPIs and cytotoxic drugs manufacturing market include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation.
